LLY Lilly (Eli)
Incretin juggernaut worth more than its price, but today's 54% margins will fade as pricing normalizes.
The story
Lilly has become the world's most valuable pharma company on the back of tirzepatide (Mounjaro/Zepbound), with orforglipron (oral) and retatrutide extending an incretin franchise that has scale, manufacturing capacity and clinical breadth few rivals can match. TTM revenue of $86B (+33% over FY) and 54% operating margins show the franchise is still in hypergrowth, financed by a heavy $19B capex build-out. Over the next decade it shifts from scarcity pricing to volume-driven maturity: Medicare/government price deals, Novo and next-wave entrants, and eventual tirzepatide patent cliffs in the late 2030s compress economics toward elite-pharma norms.
Growth (0.27), terminal growth, reinvestment, beta and the 12-year horizon stay at prior levels because TTM results confirm the story rather than change it. Target margin rises modestly from 46% to 48% (about 4% relative, not material): TTM margins of 54% prove more operating leverage than expected, but I still model them fading as GLP-1 net prices fall with government deals, oral competition and broader payer coverage. The bigger revenue base and higher margin are why value rises versus my October take.
Value drivers
| Revenue growth (Y1) | 27.0% |
| Terminal growth | 4.0% |
| Forecast horizon | 12y |
| Target operating margin | 48.0% |
| Years to target margin | 5 |
| Sales-to-capital | 1.20 |
| Beta | 0.95 |
| Failure probability | 0.0% |
| Cost of capital (WACC) | 8.4% |
| Terminal WACC | 8.7% |
Valuation bridge
| PV of explicit FCFF | 565.35B |
| PV of terminal value | 1.12T |
| Equity value | 1.65T |
| ÷ shares → per share | $1,856.88 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 109.81B | 27.0% | 53.0% | 46.67B | 19.45B | 27.21B | 25.09B |
| 2 | 137.16B | 24.9% | 51.7% | 56.92B | 22.79B | 34.13B | 29.02B |
| 3 | 168.46B | 22.8% | 50.5% | 68.23B | 26.08B | 42.15B | 33.05B |
| 4 | 203.37B | 20.7% | 49.2% | 80.34B | 29.10B | 51.24B | 37.05B |
| 5 | 241.27B | 18.6% | 48.0% | 92.90B | 31.58B | 61.31B | 40.88B |
| 6 | 281.19B | 16.5% | 48.0% | 108.27B | 33.27B | 75.00B | 46.11B |
| 7 | 321.84B | 14.5% | 48.0% | 123.92B | 33.87B | 90.05B | 51.05B |
| 8 | 361.63B | 12.4% | 48.0% | 139.24B | 33.16B | 106.08B | 55.46B |
| 9 | 398.78B | 10.3% | 48.0% | 153.54B | 30.96B | 122.58B | 59.10B |
| 10 | 431.41B | 8.2% | 48.0% | 166.10B | 27.19B | 138.91B | 61.76B |
| 11 | 457.68B | 6.1% | 48.0% | 176.22B | 21.90B | 154.32B | 63.27B |
| 12 | 475.99B | 4.0% | 48.0% | 183.27B | 15.26B | 168.01B | 63.51B |
Key risks
- GLP-1 net price erosion from Medicare/Medicaid deals, payer pushback and direct-to-consumer discounting
- Competitive entry from Novo (CagriSema, oral semaglutide), Amgen, Roche and Chinese biotechs compressing share and price
- Execution risk on the $19B+/yr manufacturing build-out and on orforglipron/retatrutide launches; late-2030s patent cliff
Catalysts
- Orforglipron global launch and uptake in primary care
- Retatrutide phase 3 readouts and outcomes-based label expansions (CV, OSA, MASH, kidney) broadening reimbursement